|Table of Contents|

SMURF2 Regulates STAT1 Ubiquitination and PromotesEMT in Prostate Cancer Cells(PDF)

《南京师大学报（自然科学版）》[ISSN:1001-4616/CN:32-1239/N]

Issue:
2021年02期
Page:
62-68
Research Field:
·生物学·
Publishing date:

Info

Title:
SMURF2 Regulates STAT1 Ubiquitination and PromotesEMT in Prostate Cancer Cells
Author(s):
Dong Jiajie; Dang Yanmei; Zhang Chi; Jiang Shun; Liu Ping; Lu Shan
School of Life Sciences,Nanjing Normal University,Institute of Biochemistry and Biological Products,Nanjing 210023,China
Keywords:
prostate cancer; SMURF2; STAT1; EMT
PACS:
Q291
DOI:
10.3969/j.issn.1001-4616.2021.02.010
Abstract:
SMURF2(smad ubiquitination regulatory factor 2)is a HECT(homologous to E6AP C terminus)family E3 ubiquitin ligase. Studies have shown that SMURF2 plays a role in promoting or suppressing cancer progression in different types of cancer. This study explored the molecular mechanism of SMURF2 regulating STAT1(signal transducers and activators of transcription 1)protein in prostate(cancer)cells. The database was firstly used to analyze the expression level of SMURF2 in different normal tissues and tumor tissues. Normal prostate cells and various prostate cancer cells were selected as experimental materials. The expression level of SMURF2 in prostate(cancer)cells was detected by RT-PCR and Western blotting assays,which found that the expression level of SMURF2 was higher in prostate cancer cells than normal prostate cells. Then the Co-IP,immunofluorescence and ubiquitination testing experiments were used to explore the effects on SMURF2 on the ubiquitination of STAT1 protein level,which found that SMURF2 can increase the ubiquitination level of STAT1 protein and further promote EMT(epithelial mesenchymal transformation)in prostate cancer cells.

References:

[1] BRAY F,FERLAY J,SOERJOMATARAM I,et al. Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. A cancer journal for clinicians,2018,68(6):394-424.
[2]CULP M B,SOERJOMATARAM I,EFSTATHIOU J A,et al. Recent global patterns in prostate cancer incidence and mortality rates[J]. European urology,2020,77(1):38-52.
[3]RUETALO N,ANDERS S,STOLLMAIER C,et al. The WW1 domain enhances autoinhibition in smurf ubiquitin ligases[J]. Journal of molecular biology,2019,431(24):4834-4847.
[4]SCHEFFNER M,KUMAR S. Mammalian HECT ubiquitin-protein ligases:biological and pathophysiological aspects[J]. Biochimica et biophysica acta,2014,1843(1):61-74.
[5]ZOU X,LEVY C G,BLANK M. Molecular functions of NEDD4 E3 ubiquitin ligases in cancer[J]. Biochimica et biophysica acta,2015,1856(1):91-106.
[6]DAVID D,NAIR S A,PILLAI M R. Smurf E3 ubiquitin ligases at the cross roads of oncogenesis and tumor suppression[J]. Biochimica et biophysica acta,2013,1835(1):119-128.
[7]KLUPP F,GIESE C,HALAMA N,et al. E3 ubiquitin ligase Smurf2:a prognostic factor in microsatellite stable colorectal cancer[J]. Cancer management and research,2019,11:1795-1803.
[8]TOMAS A,FUTTER C E,EDEN E R. EGF receptor trafficking:consequences for signaling and cancer[J]. Trends in cell biology,2014,24(1):26-34.
[9]DAVID D,JAGADEESHAN S,HARIHARAN R,et al. Smurf2 E3 ubiquitin ligase modulates proliferation and invasiveness of breast cancer cells in a CNKSR2 dependent manner[J]. Cell division,2014,9:2.
[10]DAVID D,SURENDRAN A,THULASEEDHARAN J V,et al. Regulation of CNKSR2 protein stability by the HECT E3 ubiquitin ligase Smurf2,and its role in breast cancer progression[J]. BMC cancer,2018,18(1):284.
[11]BLANK M,TANG Y,YAMASHITA M,et al. A tumor suppressor function of Smurf2 associated with controlling chromatin landscape andgenome stability through RNF20[J]. Nature medicine,2012,18(2):227-234.
[12]RAMKUMAR C,KONG Y,CUI H,et al. Smurf2 regulates the senescence response and suppresses tumorigenesis in mice[J]. Cancer research,2012,72(11):2714-2719.
[13]EMANUELLI A,MANIKOTH A D,KOGANTI P,et al. Altered expression and localization of tumor suppressive E3 ubiquitin ligase SMURF2 in human prostate and breast cancer[J]. Cancers(Basel),2019,11(4):556.
[14]WANG Z,WANG J,LI X,et al. Bortezomib prevents oncogenesis and bone metastasis of prostate cancer by inhibiting WWP1,Smurf1 and Smurf2[J]. International journal of oncology,2014,45(4):1469-1478.
[15]HELLWINKEL O J,ASONG L E,ROGMANN J P,et al. Transcription alterations of members of the ubiquitin-proteasome network in prostate carcinoma[J]. Prostate cancer and prostatic diseases,2011,14(1):38-45.
[16]TU Y,CHEN C,PAN J,et al. The ubiquitin proteasome pathway(UPP)in the regulation of cell cycle control and DNA damage repair and its implication in tumorigenesis[J]. International journal of experimental pathology,2012,5(8):726-738.
[17]JANG H H. Regulation of protein degradation by proteasomes in cancer[J]. Journal of cancer prevention,2018,23(4):153-161.
[18]HE M,ZHOU Z,SHAN A A,et al. The emerging role of deubiquitinating enzymes in genomic integrity,diseases,and therapeutics[J]. Cell bioscience,2016,6:62.
[19]KACHROO P,LEE M H,ZHANG L,et al. IL-27 inhibits epithelial-mesenchymal transition and angiogenic factor production in a STAT1-dominant pathway in human non-small cell lung cancer[J]. Journal of experimental & clinical cancer research:CR,2013,32(1):97.
[20]PAN C M,WANG M L,CHIOU S H,et al. Oncostatin M suppresses metastasis of lung adenocarcinoma by inhibiting SLUG expression through coordination of STATs and PIASs signalings[J]. Oncotarget,2016,7(37):60395-60406.

Memo

Memo:
-
Last Update: 2021-06-30